Drug updated on 11/10/2023
| Dosage Form | Injection (subcutaneous; 25 mcg, 50 mcg, 75 mcg, 100 mcg) |
| Drug Class | Hormones |
| System | Multiple |
Indication
- Indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Natpara (parathyroid hormone) Prescribing Information. | 2020 | FDA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review. | 2023 | Endocrine |
| Parathyroid hormone replacement versus oral calcium and active vitamin d supplementation in hypoparathyroidism: a meta-analysis. | 2020 | Indian Journal of Endocrinology and Metabolism |
| Calcium, vitamin D or recombinant parathyroid hormone for managing postâthyroidectomy hypoparathyroidism. | 2019 | Cochrane Database of Systematic Reviews |
Ongoing and completed studies: ClinicalTrials.gov